Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for full year 2022, after U.S. markets close on Wednesday, March 1, 2023.
Following the release, Alvotech will conduct a business update conference call with the investment community on Thursday, March 2, 2023, at 8:00 am ET (13:00 pm GMT). Live audio of the conference call will be webcast and available to members of the news media, investors and the general public.
Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor website https://investors.alvotech.com and can be found under News and Events – Events and Presentations. The webcast will be archived and available for replay for 90 days after the event on Alvotech’s website under News and Events – Events and Presentations
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
CONTACTS
Alvotech Investor Relations
Benedikt Stefansson
alvotech.ir[at]alvotech.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
SalMar - Invitasjon til presentasjon av resultater for første kvartal 20248.5.2024 20:00:00 CEST | Pressemelding
SalMar presenterer resultater for første kvartal 2024 tirsdag 14. mai 2024 klokken 08:00 på Hotel Continental, Stortingsgaten 24/26 i Oslo. Konsernsjef Frode Arntsen og CFO Ulrik Steinvik vil være til stede fra selskapet. Presentasjonen vil i tillegg være tilgjengelig via norsk webcast på selskapets hjemmeside, www.salmar.no, fra 08:00. Det vil være mulig å sende inn spørsmål under presentasjonen. Engelsk webcast (opptak) vil være tilgjengelig fra 10:00 på www.salmar.no. Det vil bli arrangert to gruppekonferanser i etterkant av presentasjonen, en fysisk presentasjon på norsk klokken 12:00 og en digital konferanse på engelsk klokken 15:00. For å delta, vennligst registrer deg hos Arctic Securities, https://forms.office.com/e/TaJu8MbQkN. Resultatene offentliggjøres klokken 06:30 på selskapets hjemmeside, www.salmar.no og på Oslo Børs Nyhetssider www.newsweb.no. For mer informasjon, kontakt: Håkon Husby, IR-ansvarlig Tel: +47 936 30 449 Email: hakon.husby@salmar.no Denne opplysningen er i
SalMar - Invitation to presentation of the first quarter 2024 results8.5.2024 20:00:00 CEST | Press release
SalMar presents results for the first quarter 2024 on Tuesday 14 May 2024 at 08:00 CEST. The presentation will be held at Hotel Continental in Stortingsgaten 24/26 in Oslo. CEO Frode Arntsen and CFO Ulrik Steinvik will be representing the company. The presentation will in addition be available on Norwegian webcast at 08:00 CEST on www.salmar.no. There will be opportunity to send in questions during the Norwegian presentation. An English webcast (recording) will be available from 10:00 CEST on www.salmar.no. After the presentation two group conferences will be arranged, one physical presentation in Norwegian at 12:00 CEST and one digital presentation in English at 15:30 CEST. For registration please register to Arctic Securities, https://forms.office.com/e/TaJu8MbQkN. The results will be available from 06:30 CEST at the company's homepage, www.salmar.no and Oslo Stock Exchange's page, www.newsweb.no. For more information, please contact: Håkon Husby, Head of Investor Relations Tel: +47
EMGS reports first quarter 2024 results8.5.2024 20:00:00 CEST | Press release
Electromagnetic Geoservices ASA’s (“EMGS” or the “Company”) financial report and market presentation for the first quarter of 2024 are attached. Summary: * The Company recorded revenues of USD 0.2 million, down from USD 5.0 million in the first quarter of 2023 and down from USD 1.1 million in the fourth quarter of 2023. * Adjusted EBITDA (including capitalised multi-client expenses and vessel and office lease expenses) of negative USD 3.8 million, down from USD 2.4 million in the first quarter of 2023. * Free cash decreased with USD 1.6 million during the quarter, to USD 8.7 million. * The Atlantic Guardian completed the acquisition of the fully prefunded multi-client survey in the North Sea and started transiting towards Brazil. A pre-recorded presentation will be available over the internet from 20:00 (local time Norway) today. To access the presentation, please go to the Company’s homepage (www.emgs.com) and follow the link. Contact Anders Eimstad, Chief Financial Officer, +47 94 82
Interoil Annual report 2023 published8.5.2024 19:53:29 CEST | Press release
Oslo, 8 May 2024 Please find attached the 2023 Annual report for Interoil Exploration and Production ASA and the independent audit report prepared by PricewaterhouseCoopers AS. The company publishes its annual financial statements also in European Single Electronic Format (ESEF), available in a zip file as an attachment (named Interoil-Exploration-and-Production-2023-12-31-en) to this release. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act. *************************** Please direct any further questions to ir@interoil.no About Interoil Interoil Exploration and Production ASA is a Norwegian based exploration and production company - listed on the Oslo Stock Exchange with focus on Latin America. The Company is operator and license holder of several production and exploration assets in Colombia and Argentina with headquarter in Oslo. Attachments Annual report 2023 with audit opinionInteroil-Exploration-and-Produ
Weekly share repurchase program transaction details8.5.2024 18:41:09 CEST | Press release
May 8, 2024 SBM Offshore reports the transaction details related to its EUR65 million (c. US$70 million) share repurchase program for the period May 2, 2024 through May 8, 2024. The repurchases were made under the EUR65 million share repurchase program announced on February 29, 2024 and effective from March 1, 2024. The objective of the program is to reduce share capital. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period March 1, 2024 through May 8, 2024 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website. Share Repurchase ProgramOverall progress Share Repurchase Program: Total Repurchase Amount EUR 65,000,000 Cumulative Repurchase Amount EUR 15,064,569 Cumulative Quantity Repurchased 1,059,438 Cumulative